Sumitomo Chemical India Ltd
SUMICHEMSumitomo Chemical India Ltd's earnings have outrun its stock. EPS grew +7.4% in a year against a −11.2% price move.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is building a base (6 weeks in) while the P/E sits at the 44th percentile of its own 6-year range. Underneath, the last four quarters read improving — profit +11.0% year on year, and 117% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sumitomo Chemical India Ltd trades at ₹539, building a base and 6 weeks into that stage. That is +16.0% against its own 200-day average. It sits at 72% of a 52-week range of ₹375 to ₹602. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is building a base — week 6 of stage 1. At ₹539 it trades +16.0% versus its 200-day average and sits at 72% of its 52-week range (₹375–₹602).
Against the market, two honest reads. Cumulative: over the last 6.5 years the stock moved +133% while the NIFTY 500 moved +135% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 44th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sumitomo Chemical India Ltd trades at 50.9× P/E, mid-range by its own standards (44th percentile). Its long-run median P/E is 51.7×, measured across 6.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 50.9× is mid-range by its own standards (44th percentile), against a long-run median of 51.7× measured over 6.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +7.4% against a −11.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +4.2%/yr price move, ~+8.5%/yr came from earnings growth and ~−4.3 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sumitomo Chemical India Ltd reads as topping out on its fundamental arc. Topping out — profit and EPS growth have decelerated hard (profit growth +37.0% at its peak → +7.1% latest) while ROCE still reads 22.0%. The read is built from 12 quarters across 4 curves, on partial evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +2.8% | −2.7% | +4.1% | — |
| Profit | +7.3% | +2.7% | +9.5% | — |
| EPS | +7.4% | +2.6% | +9.5% | — |
| Share price | −11.2% | +8.9% | +4.2% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
47.6/100 — rank 16 of 24 in Pesticides/Agrochemicals · 87% evidence confidence
Sumitomo Chemical India Ltd scores 47.6 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 16. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 14.5 + 18.9 + 4 + 10.2 = 47.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sumitomo Chemical India Ltd reported ₹684 Cr of revenue in the Mar 26 quarter, +0.7% year on year. Over 8 years it has compounded at 6.8% a year. The last full year, FY26, came in at ₹3,238 Cr. The last four reported quarters add to ₹3,239 Cr.
Sumitomo Chemical India Ltd reported ₹684 Cr of revenue in the Mar 26 quarter, +0.7% year on year. Over 8 years it has compounded at 6.8% a year. The last full year, FY26, came in at ₹3,238 Cr. The last four reported quarters add to ₹3,239 Cr.
FY26 revenue came in at ₹3,238 Cr (+2.8% on the year), capping 8 years at 6.8% compound. The latest quarter (Mar 26) printed ₹684 Cr, +0.7% year on year.
Pace check: the last four quarters averaged +2.3% growth against the decade's 6.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +2.9% over the last 4 quarters against +6.7%/yr over the last 8 — rolling over; TTM profit +7.1% vs +21.1%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 20.0% this quarter (+2.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sumitomo Chemical India Ltd's operating margin is 20.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 9 fiscal years the operating margin has ranged 11.0% to 21.0%. The current quarter sits inside that band.
Sumitomo Chemical India Ltd's operating margin is 20.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 9 fiscal years the operating margin has ranged 11.0% to 21.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 20.0%, +2.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 11.0%–21.0%, and FY26's 21.0% is the top of that band — a record year.
Why the margin moved: operating margin went +2.0 pp year on year while gross margin went +2.2 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit +11.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sumitomo Chemical India Ltd earned ₹111 Cr of net profit in the Mar 26 quarter, +11.0% year on year. Full-year FY26 profit was ₹543 Cr. The 8-year compound rate is 17.9%. That is 16.2% of the quarter's revenue. The same quarter a year earlier earned ₹100 Cr.
Sumitomo Chemical India Ltd earned ₹111 Cr of net profit in the Mar 26 quarter, +11.0% year on year. Full-year FY26 profit was ₹543 Cr. The 8-year compound rate is 17.9%. That is 16.2% of the quarter's revenue. The same quarter a year earlier earned ₹100 Cr.
Mar 26 profit was ₹111 Cr, +11.0% year on year. On the full year, FY26 printed ₹543 Cr (+7.3%), and the 8-year compound rate is 17.9%.
Why profit moved: revenue contributed +0.7% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +7.7% vs revenue +2.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 117% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 117% of Sumitomo Chemical India Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹446 Cr of operating cash against ₹543 Cr of profit. After ₹79.0 Cr of capital spending, ₹367 Cr was left as free cash.
FY26: operating cash of ₹446 Cr against reported profit of ₹543 Cr, leaving free cash of ₹367 Cr after ₹79.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 117% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 117%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
→ So follow the cash to where it goes. Next: a 163-day cycle and ₹290 Cr of building.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sumitomo Chemical India Ltd's cash conversion cycle runs 163 days in FY26, up from 157 days in FY21. Capital spending ran ₹290 Cr over the last 3 years. At FY26 sales of ₹3,238 Cr each day of that cycle holds about ₹8.9 Cr, so roughly ₹1,446 Cr sits inside the business at any moment.
FY26: debtors at 83 days, inventory at 166 days — roughly 5.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 163 days, looser than FY21's 157.
The full loop: cash goes out to suppliers and production on day 0; stock waits 166 days to sell; customers pay about 83 days after that; and suppliers themselves are paid at 86 days — netting out to the 163-day cycle.
In money terms: at FY26 sales of ₹3,238 Cr, each day of the cycle holds about ₹8.9 Cr — so the 163-day loop keeps roughly ₹1,446 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹290 Cr over the last 3 fiscal years against ₹194 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹20.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 22% and the ROIC − WACC spread is +9.3 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Sumitomo Chemical India Ltd earns a ROCE of 22% in FY26. That is up from a trough of 20% in FY24. Return on invested capital clears the cost of that capital by +9.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 16.8% net margin on 0.72× asset turns.
FY26 ROCE is 22%, recovered from a FY24 trough of 20% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 16.8% net margin × 0.72× asset turns × 1.32× balance-sheet leverage ≈ 16.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 21.3% − 12.0% = a +9.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.02.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Sumitomo Chemical India Ltd carries total debt of ₹63.0 Cr against shareholder equity of ₹3,394 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.02 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹63.0 Cr against shareholder equity of ₹3,394 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.02 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 2.2 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 2.2 points of Sumitomo Chemical India Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 9.3% of the company. Promoters moved +0.0 points over the same window, to 75.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +2.2 points over 8 quarters to 9.3%; Promoters: +0.0 points over 8 quarters to 75.0%; Foreign institutions: +0.0 points over 8 quarters to 3.0%.
Why the register moved: domestic institutions drove it (+2.2 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sumitomo Chemical India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Sumitomo Chemical India Ltd this page | 50.9× | ₹25,978 Cr | Mixed | |||
| UPL Ltd | 28.2× | ₹50,841 Cr | No read | |||
| P I Industries Ltd | 34.5× | ₹41,437 Cr | Deteriorating | |||
| Bayer CropScience Ltd | 385.0× | ₹18,954 Cr | — | — | — | — |
| Jubilant Ingrevia Ltd | 36.3× | ₹11,557 Cr | Mixed | |||
| Sharda Cropchem Ltd | 12.1× | ₹7,876 Cr | Mixed | |||
| Epigral Ltd | 15.2× | ₹5,016 Cr | Mixed | |||
| NACL Industries Ltd | 178.0× | ₹4,610 Cr | No read | |||
| Dhanuka Agritech Ltd | 15.5× | ₹4,517 Cr | Topping out | |||
| Rallis India Ltd | 26.9× | ₹4,253 Cr | Mixed | |||
| Bhagiradha Chemicals & Industries Ltd | 188.0× | ₹3,416 Cr | Improving | |||
| GSP Crop Science Ltd | 24.4× | ₹2,468 Cr | — | — | — | — |
| Bharat Rasayan Ltd | 13.1× | ₹2,096 Cr | Mixed | |||
| Insecticides India Ltd | 12.9× | ₹1,793 Cr | Mixed | |||
| India Pesticides Ltd | 14.4× | ₹1,727 Cr | Mixed | |||
| Titan Biotech Ltd | 57.5× | ₹1,719 Cr | Turning around | |||
| Astec Lifesciences Ltd | — | ₹1,469 Cr | No read | |||
| Meghmani Organics Ltd | 48.2× | ₹1,385 Cr | No read | |||
| Punjab Chemicals & Crop Protection Ltd | 21.0× | ₹1,375 Cr | Mixed | |||
| Excel Industries Ltd | 15.5× | ₹1,172 Cr | Mixed | |||
| Titan Biotech Ltd | 42.0× | ₹1,141 Cr | Turning around | |||
| Dharmaj Crop Guard Ltd | 16.1× | ₹882 Cr | No read | |||
| Advance Agrolife Ltd | 20.0× | ₹706 Cr | No read | |||
| Heranba Industries Ltd | — | ₹700 Cr | No read | |||
| Best Agrolife Ltd | 60.6× | ₹538 Cr | No read |
Frequently asked questions
What is Sumitomo Chemical India Ltd's share price today?
Sumitomo Chemical India Ltd trades at ₹539, −11.2% over the past year. The company is valued at ₹25,978 Cr. The stock sits at 72% of its 52-week range of ₹375–₹602, +16.0% versus its 200-day average. On the tape, the price is building a base, 6 weeks in. — as of 24 July 2026.
What were Sumitomo Chemical India Ltd's latest quarterly results?
Sumitomo Chemical India Ltd reported revenue of ₹684 Cr and net profit of ₹111 Cr for the Mar 26 quarter. Revenue rose 0.7% and profit rose 11.0% year on year. Earnings per share were ₹2.23. The operating margin was 20.0%, 2.0 pp higher than a year earlier. — as of 24 July 2026.
What is Sumitomo Chemical India Ltd's revenue?
Sumitomo Chemical India Ltd reported revenue of ₹684 Cr in the Mar 26 quarter, +0.7% year on year. For the full FY26 fiscal year, revenue was ₹3,238 Cr (+2.8%). Over the last 8 years revenue compounded at 6.8% a year. — as of 24 July 2026.
What is Sumitomo Chemical India Ltd's profit?
Sumitomo Chemical India Ltd earned ₹111 Cr of net profit in the Mar 26 quarter, +11.0% year on year. Full-year FY26 profit was ₹543 Cr. The operating margin ran 20.0% in the latest quarter. — as of 24 July 2026.
What is Sumitomo Chemical India Ltd's market cap?
Sumitomo Chemical India Ltd's market capitalisation is ₹25,978 Cr at a share price of ₹539. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Sumitomo Chemical India Ltd's P/E ratio?
Sumitomo Chemical India Ltd trades at a P/E of 50.9×, at the 44th percentile of its own 6-year range, against a long-run median of 51.7×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Sumitomo Chemical India Ltd pay a dividend?
Yes — Sumitomo Chemical India Ltd's dividend payout was 12% of profit in FY26, and it recorded a payout in 8 of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Sumitomo Chemical India Ltd overvalued?
On its own history, Sumitomo Chemical India Ltd looks mid-range against its own history: its P/E of 50.9× sits at the 44th percentile of its 6-year range (long-run median 51.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Sumitomo Chemical India Ltd growing?
Yes — Sumitomo Chemical India Ltd is growing: latest-quarter revenue +0.7% year on year, profit +11.0%, and the margin +2.0 pp at 20.0%. The 8-year compound rates are 6.8% (revenue) and 17.9% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Sumitomo Chemical India Ltd performing?
Sumitomo Chemical India Ltd is building a base, 6 weeks in. Its latest quarter's revenue rose 0.7% and profit rose 11.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Sumitomo Chemical India Ltd in?
Topping out — profit and EPS growth have decelerated hard (profit growth +37.0% at its peak → +7.1% latest) while ROCE still reads 22.0%. The read comes from the last 12 quarters of growth (revenue growth +2.9% latest, profit growth +7.1% latest, eps growth +7.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Sumitomo Chemical India Ltd in an uptrend?
No — the price is building a base (week 6 of stage 1), trading +16.0% versus its 200-day average and at 72% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Sumitomo Chemical India Ltd beating the market?
On recent form, yes — Sumitomo Chemical India Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 6.5 years the stock moved +133% against the NIFTY 500's +135% — behind the index over the full window. — as of 24 July 2026.
Will Sumitomo Chemical India Ltd's share price go up?
This page publishes no price forecast for Sumitomo Chemical India Ltd. What it measures instead: the share price is ₹539, the price is building a base 6 weeks in. Its P/E of 50.9× sits at the 44th percentile of its own 6-year range. — as of 24 July 2026.
Who owns Sumitomo Chemical India Ltd?
Promoters hold 75.0% of Sumitomo Chemical India Ltd, foreign institutions 3.0%, domestic institutions 9.3% and the public 12.7% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 2.2 points over 8 quarters. — as of 24 July 2026.
Does Sumitomo Chemical India Ltd have too much debt?
No — Sumitomo Chemical India Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill 84×. FY26 borrowings were ₹63.0 Cr against equity of ₹3,390 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Sumitomo Chemical India Ltd's capex?
Sumitomo Chemical India Ltd spent ₹290 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹79.0 Cr, with ₹20.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Sumitomo Chemical India Ltd's cash flow?
Sumitomo Chemical India Ltd generated ₹446 Cr of operating cash flow in FY26 and ₹367 Cr of free cash flow after ₹79.0 Cr of capital spending. Reported profit that year was ₹543 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Sumitomo Chemical India Ltd's profit real cash?
Yes — over the last 3 fiscal years, 117% of Sumitomo Chemical India Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹446 Cr against reported profit of ₹543 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Sumitomo Chemical India Ltd in its business cycle?
Sumitomo Chemical India Ltd's FY26 operating margin was 21.0%, against a 9-year band of 11.0%–21.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Sumitomo Chemical India Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Sumitomo Chemical India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sumitomo Chemical India Ltd's earnings have outrun its stock. EPS grew +7.4% in a year against a −11.2% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.